BOSTON, April 15, 2015 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced the completion of its sales restructuring program which began on January 4, 2015. The restructuring was implemented to conserve capital and to align the organization to a new commercial strategy built on third party distribution partners. Reflecting some impact from the transition, as well as the trend towards drug eluting stent use in STEMI patients discussed during our fourth quarter 2014 earnings call last month, total revenues for the first quarter 2015 were approximately $500,000, down sequentially from $850,000 in the fourth quarter 2014.
Hansen Medical has announced that the company’s Magellan 10F robotic catheter has received the CE mark for use in the peripheral vasculature. Achieving this milestone allows the company to market the Magellan 10F robotic catheter in Europe and other countries that require the CE mark.
Medtronic announced on 14 April 2015 that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health.
Medtronic has initiated the US launch of the HawkOne directional atherectomy system. The HawkOne system can be used to treat all plaque morphologies in patients with peripheral arterial disease, including patients who have plaque blockages that have become severely calcified.
Many nursing home residents who underwent lower extremity revascularization died, did not walk or had functional decline following the procedure, which is commonly used to treat leg pain caused by peripheral arterial disease, wounds that will not heal or worsening gangrene, according to an article published online by JAMA Internal Medicine.
Hatch Medical has successfully brokered the sale of Novotek Innovation’s novel intellectual property portfolio for endovascular repair of abdominal aortic aneurysms. The undisclosed purchase price consisted of a combined cash and stock payment.
The EverFlex self-expanding peripheral stent system from Medtronic has been proven to provide sustained patency in the treatment of long, complex lesions in the superficial femoral and popliteal arteries, according to the three-year results of the DURABILITY II study, which are reported in Catheterization and Cardiovascular Intervention.
MicroPort Endovascular has announced that 18 patients have now been enrolled in a pre-market clinical study to assess the efficacy and safety of the company’s Minos ultra-low profile abdominal aortic stent graft system to treat infrarenal abdominal aortic aneurysms.
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Simultaneously, Lixiana has received marketing authorisation in Switzerland for the treatment of adult patients with venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), following previous treatment with fractionated or unfractionated heparin for five days, as well as for the prevention of recurrent VTE.
Inari Medical has treated the first patient with its FlowTriever infusion aspiration system. The FlowTriever system received 510(k) marketing clearance from the US Food and Drug Administration (FDA) in February to treat emboli in the peripheral vasculature.
CryoLife has provided an update on its ongoing litigation with CR Bard and some of its subsidiaries regarding PerClot. The US District Court for the District of Delaware has allowed CryoLife’s declaratory judgement lawsuit against CR Bard’s Medafor subsidiary to proceed. The court also granted Medafor’s motion for a preliminary injunction with respect to CryoLife’s marketing and sale of PerClot Topical in the USA. CryoLife is currently awaiting the court’s order, which it expects will provide details regarding the scope of the injunction.
ArtVentive Medical has announced the first use of its Endoluminal Occlusion System (EOS) in the USA at The Johns Hopkins Hospital in Baltimore, where Kelvin Hong and Anobel Tamrazi performed a splenic artery occlusion using the device.
At the Leipzig Interventional Course (LINC, 27–30 January, Leipzig, Germany), Michael Lichtenberg, chief of the Vascular Center Klinikum Arnsberg, Arnsberg, Germany, presented information about a new balloon dilatation catheter that allows a targeted injection of fluids during percutaneous transluminal angioplasty.
ClearFlow is currently exhibiting its PleuraFlow Active Clearance Technology system at the 34th annual Association of Physician Assistants in Cardiovascular Surgery (APACVS) meeting (1–4 March, Las Vegas, USA). PleuraFlow will also be displayed at the Maquet Medical Systems USA booth until 4 March. Maquet is the exclusive distributor of ClearFlow’s PleuraFlow system in the USA.
Cardinal Health announced on 2 March 2015 plans to acquire Johnson & Johnson’s Cordis business, a global manufacturer of cardiology and endovascular devices, for US$1.944 billion in cash, or approximately US$1.594 billion, net of the present value of tax benefits.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos